ASXL1 mutations have been shown to induce alternative splicing in mutated cell lines [78], however, determining whether the alternative splicing events of RUNX3 in BOS and AML-ASXL1 are primary effects of ASXL1 mutations is beyond the scope of this study. This evidence concerns the gene RUNX3 and acute myeloid leukemia.